Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment

Journal of the American College of Cardiology

Volumn 31, Issue 4, 1998, Pages 776-779

  Steg, P Gabriel ^a   Laperche, Thierry ^a   Golmard, Jean Louis ^b   Juliard, Jean Michel ^a   Benamer, Hakim ^a   Himbert, Dominique ^a   Aubry, Pierre ^a  

^a BICHAT HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD VESSEL DIAMETER; DRUG EFFICACY; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OBSERVER VARIATION; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROBABILITY; SURVIVAL RATE;

EID: 0032520991     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00018-7     Document Type: Article

References (15)

1. 1. The GUSTO Angiographic Investigators. The effects of tPA, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
2. 2. Stadius ML. Angiographic monitoring of reperfusion therapy for acute myocardial infarction: TIMI grade 3 perfusion is the goal. Circulation 1993;87:2055-7.
3. 3. Kennedy JW. Optimal management of acute myocardial infarction requires early and complete reperfusion. Circulation 1995;91:1905-7.
4. 4. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tPA and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-54.
5. 5. Anderson JL, Rothbard RL, Hackworthy RA, et al., for the APSAC Multicenter Investigators. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. J Am Coll Cardiol 1988;11:1153-63.
6. 6. Leizorovicz A, Boissel JP, Robert F. Coronary reperfusion rates in acute myocardial infarction patients after thrombolytic treatment with anistreplase: correlation with the delay from onset of symptoms to treatment. A review of 424 case records of patients admitted to coronary reperfusion studies with anistreplase. J Cardiovasc Pharmacol 1992;19:34-9.
7. 7. Laperche T, Steg PG, Dehoux M, et al., for the PERM Study Group. A study of biochemical markers of reperfusion early after thrombolysis for acute myocardial infarction. Circulation 1995;92:2079-86.
8. 8. Juliard JM, Himbert D, Golmard JL, et al. Can we provide reperfusion therapy to all unselected patients admitted with acute myocardial infarction? J Am Coll Cardiol 1997;30:157-64.
9. 9. Cox DR, Kinkley DV. Theoretical Statistics. Cambridge (UK): University Press, 1974.
10. 10. Agresti A. Categorical Data Analysis. New York: John Wiley, 1990.
11. 11. Zeymer U, Tebbe U, von Essen R, Vogt A, Neuhaus KL, for the ALLK Study Group. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens [abstract]. Circulation 1996;94 Suppl I:I-440.
12. 12. Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis: effects of molecular form and dose of activator, age of the thrombus and route of administration. J Clin Invest 1983;71:368-76.
13. 13. Sakharov AV, Nagelkerke F, Rijken DC. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. J Biol Chem 1996;271:2133-8.
14. 14. The Gusto Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
15. 15. Gibson CM, Cannon CP, Daley WL, et al. TIMI count frame: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88.